{"schema_version":"secwatch.filing_event.v1","accession":"0001842952-25-000085","form_type":"8-K","ticker":"CNTX","cik":"0001842952","company_name":"Context Therapeutics Inc.","filed_at":"2025-09-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.310105+00:00","generated_at":"2026-05-17T08:57:25.324657+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Context Therapeutics receives Nasdaq extension until Feb 23, 2026 for bid price compliance","bullets":["Received Nasdaq extension letter on Aug 28, 2025; new compliance deadline Feb 23, 2026.","Originally notified of non-compliance on Feb 27, 2025; need $1.00 closing bid for 30 consecutive days.","Company may consider reverse stock split to regain bid price compliance.","Listing and trading of CNTX common stock unaffected by extension letter."],"urls":{"canonical":"https://secwatch.observer/filing/0001842952-25-000085","json":"https://secwatch.observer/filing/0001842952-25-000085.json","markdown":"https://secwatch.observer/filing/0001842952-25-000085.md","text":"https://secwatch.observer/filing/0001842952-25-000085.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842952/000184295225000085/0001842952-25-000085-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842952/000184295225000085/cntx-20250828.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:57:25.324657+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"89ae151671131cb7c409ea6a6fabfcd0afc5d1b3","claim":"Context Therapeutics Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"August 28, 2025, Context Therapeutics Inc. (the “Company”) received written notice (the “Extension Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that Nasdaq granted the Company an additional 180 calendar days, or until February 23, 2026 (the “Extension Deadline”), to regain compliance with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”). The Extension Letter has no immediate effect on the Nasdaq listing or trading of the Company’s common stock. As previously disclosed, on February 27, 2025, the Company received written notice from Nasdaq stating that","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1842952/000184295225000085/0001842952-25-000085-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"extension granted"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}